The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

39 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Combining Elements from Two Antagonists of Formyl Peptide Receptor 2 Generates More Potent Peptidomimetic Antagonists.EBI
University of Copenhagen
Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.EBI
University of Warsaw
Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.EBI
University of Bari Aldo Moro
Pachymodulin, a new functional formyl peptide receptor 2 peptidic ligand isolated from frog skin has Janus-like immunomodulatory capacities.EBI
Sorbonne University
6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.EBI
Universita Degli Studi Di Firenze
Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.EBI
Queen Mary University of London
Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents.EBI
Amgen
Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders.EBI
University of Bari Aldo Moro
Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists.EBI
Bristol Myers Squibb Research and Development
Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists.EBI
Queen Mary University of London
Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation.EBI
Queen Mary University of London
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.EBI
Kyorin Pharmaceutical
Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin AEBI
University College Dublin
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.EBI
Shanghaitech University
Substituted Pyridazin-3(2 H)-ones as Highly Potent and Biased Formyl Peptide Receptor Agonists.EBI
Monash University
FPRL-1 Receptor Modulators May Provide Treatment for Inflammation.EBI
Therachem Research Medilab (India)
Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.EBI
University of Bari Aldo Moro
CASEIN KINASE 1 DELTA MODULATORSBDB
Janssen Pharmaceutica
PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USEBDB
Akebia Therapeutics
Protacs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereofBDB
Shaanxi Panlong Pharmaceutical
Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonistsBDB
Glycomimetics.
Sultam compound and application method thereofBDB
Chai Tai Tianqing Pharmaceutical Group
Substituted tricyclic compounds as FGFR inhibitorsBDB
Incyte
Compounds and their uses as ACC inhibitorsBDB
Nanjing Ruijie Pharmatech
GCN2 inhibitors and uses thereofBDB
Merck Patent
Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereofBDB
Shanghai Haiyan Pharmaceutical Technology
Selective Bruton's tyrosine kinase inhibitor and use thereofBDB
Hangzhou Hertz Pharmaceutical
CompoundsBDB
Exonate
Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinaseBDB
University Of Texas
Factor IXa inhibitorsBDB
Merck Sharp & Dohme
Heteroaryls and uses thereofBDB
Millennium Pharmaceuticals
α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereofBDB
Merck Serono
Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-a converting enzyme (TACE/ADAM-17).BDB
China Pharmaceutical University
Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidaseBDB
University of California
Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.BDB
Abbott Laboratories
Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase).BDB
University of Illinois At Chicago
5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.BDB
Bristol-Myers Squibb
4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.BDB
Tsukuba Research Laboratories